n,n-dimethylarginine has been researched along with fluorobenzenes in 3 studies
| Studies (n,n-dimethylarginine) | Trials (n,n-dimethylarginine) | Recent Studies (post-2010) (n,n-dimethylarginine) | Studies (fluorobenzenes) | Trials (fluorobenzenes) | Recent Studies (post-2010) (fluorobenzenes) |
|---|---|---|---|---|---|
| 2,216 | 228 | 1,221 | 3,032 | 581 | 1,214 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cottin, Y; Delemasure, S; Duvillard, L; Guilland, JC; Korandji, C; Lauzier, B; Rochette, L; Segueira-Le Grand, A; Sicard, P; Vergely, C; Zeller, M | 1 |
| Ishibashi, Y; Matsui, T; Nakamura, K; Ohta, K; Okuda, S; Takeuchi, M; Tanoue, R; Ueda, S; Yamagishi, S | 1 |
| Akturk, E; Altas, Y; Atas, H; Balta, S; Can, C; Demirkol, S; Erdem, K; Korkmaz, H; Kurtoglu, E; Sincer, I; Yilmaz, M | 1 |
1 trial(s) available for n,n-dimethylarginine and fluorobenzenes
| Article | Year |
|---|---|
Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease.
Topics: Arginine; Atorvastatin; Biomarkers; Coronary Angiography; Coronary Stenosis; Down-Regulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome; Turkey | 2014 |
2 other study(ies) available for n,n-dimethylarginine and fluorobenzenes
| Article | Year |
|---|---|
Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Arginine; Blood Pressure; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-4; Male; NADPH Oxidases; Oxidative Stress; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reactive Oxygen Species; Rosuvastatin Calcium; Sulfonamides | 2008 |
Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level.
Topics: Amidohydrolases; Apoptosis; Arginine; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Fluorobenzenes; Glycation End Products, Advanced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules, Proximal; Pravastatin; Pyrimidines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Up-Regulation | 2012 |